Animals that cannot sense endotoxin may die if they are infected by Gram-negative bacteria. Animals that sense endotoxin and respond too vigorously may also die, victims of their own inflammatory reactions. The outcome of Gram-negative bacterial infection is thus determined not only by an individual's ability to sense endotoxin and respond to its presence, but also by numerous phenomena that inactivate endotoxin and/or prevent harmful reactions to it. Endotoxin sensing requires the MD-2/TLR4 recognition complex and occurs principally in local tissues and the liver. This review highlights the known detoxification mechanisms, which include: (i) proteins that facilitate LPS sequestration by plasma lipoproteins, prevent interactions between the bioactive lipid A moiety and MD-2/TLR4, or promote cellular uptake via non-signaling pathway(s); (ii) enzymes that deacylate or dephosphorylate lipid A; (iii) mechanisms that remove LPS and Gram-negative bacteria from the bloodstream; and (iv) neuroendocrine adaptations that modulate LPS-induced mediator production or neutralize pro-inflammatory molecules in the circulation. In general, the mechanisms for sensing and detoxifying endotoxin seem to be compartmentalized (local versus systemic), dynamic, and variable between individuals. They may have evolved to confine infection and inflammation to extravascular sites of infection while preventing harmful systemic reactions. Integration of endotoxin sensing and detoxification is essential for successful host defense.
Cross AS, Sadoff JC, Kelly N., Bernton E., Gemski P.Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin 1 a protects mice from lethal bacterial infection. J Exp Med1989; 169: 2021—2027.
2.
Gioannini TL , Teghanemt A., Zarember KA, Weiss JPRegulation of interactions of endotoxin with host cells. J Endotoxin Res2003; 9: 401—408.
3.
Kennedy MN, Mullen Ged, Leifer CA et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem2004; 279: 34698—34704.
4.
Gioannini TL , Teghanemt A., Zhang D. et al. Isolation of an endotoxin—MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA2004 ; 101: 4186-4191.
5.
Gegner JA, Ulevitch RJ, Tobias PSLipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem1995; 270: 5320—5326.
6.
Henneke P., Golenbock DTInnate immune recognition of lipopolysaccharide by endothelial cells . Crit Care Med2002; 30(5 Suppl): S207—S213.
Park CT, Creasey AA, Wright SDTissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood1997; 89: 4268—4274.
15.
Chaby R.Lipopolysaccharide-binding molecules: transporters, blockers and sensors . Cell Mol Life Sci2004; 61: 1697—1713.
16.
Reid RR, Prodeus AP, Khan W., Hsu T., Rosen FS, Carroll MCEndotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol1997; 159: 970—975.
17.
Boes M., Prodeus AP, Schmidt T., Carroll MC, Chen J.A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med1998; 188: 2381—2386.
18.
Fischer MB, Prodeus AP, Nicholson-Weller A. et al. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol1997; 159: 976—982.
19.
Munford RS, Dietschy JMEffects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis1985; 152: 177—184.
20.
Hoffmann JA , Kafatos FC, Janeway Jr CA, Ezekowitz RAB. Phylogenetic perspective in innate immunity. Science1999 ; 284: 1313—1318.
21.
Zhao L., Ohtaki Y., Yamaguchi K. et al. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood2002; 100: 3233—3239.
22.
Weiss J.Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans2003; 31: 785—790.
23.
Levy O.Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol1996; 56: 263—277.
24.
Tobias PS, Soldau K., Iovine NM, Elsbach P., Weiss J.Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chem1997 ; 272: 18682—18685.
25.
Nagaoka I., Hirota S., Niyonsaba F. et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-α by blocking the binding of LPS to CD14+ cells. J Immunol2001; 167: 3329—3338.
Kitchens RL , Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res2003; 44: 2339—2348.
30.
Read TE, Grunfeld C., Kumwenda ZL et al. Triglyceride-rich lipoproteins prevent septic death in rats . J Exp Med1995; 182: 267—272.
31.
Harris HW, Grunfeld C., Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest1993; 91: 1028—1034.
32.
Van Oosten MV , Rensen Pcn, Van Amersfoort ES et al. Apolipoprotein E protects against-bacterial lipopolysaccharide-induced lethality — a new therapeutic approach to treat Gram-negative sepsis. J Biol Chem2001; 276: 8820—8824.
33.
Rensen Pcn, Van Oosten M., Van de Bilt E., Van Eck M., Kuiper J., Van Berkel Tjc.Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest1997; 99: 2438—2445.
34.
Kasravi FB, Welch WJ, Peters-Lideu CA, Weisgraber KH, Harris HWInduction of cytokine tolerance in rodent hepatocytes by chylomicron-bound LPS is LDL receptor-dependent. Shock2003; 19: 157—162.
35.
Quezado ZM, Natanson C., Banks SM et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of Gram-negative septic shock. J Pharmacol Exp Ther1995; 272: 604—611.
36.
Kitchens RL , Thompson PA, Viriyakosol S., O'Keefe GE, Munford RSPlasma CD14 decreases monocyte responses to LPS by promoting the transfer of cell-bound LPS to plasma lipoproteins. J Clin Invest2001; 108: 485—493.
37.
Kitchens RL , Wolfbauer G., Albers JJ, Munford RSPlasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem1999; 274: 34116—34122.
38.
Hall CL, Munford RSEnzymatic deacylation of the lipid A moiety of Salmonella typhimurium lipopolysaccharides by human neutrophils. Proc Natl Acad Sci USA1983; 80: 6671—6675.
39.
Golenbock DT , Hampton RY, Raetz Crh.Lipopolysaccharide antagonism by lipid A precursor lipid IVA is species dependent. FASEB J1990; 4: A2055.
40.
Weinrauch Y. , Katz SS, Munford RS, Elsbach P., Weiss J.Deacylation of purified LPS by cellular and extracellular components of a sterile rabbit peritoneal inflammatory exudate . Infect Immun1999; 67: 3376—3382.
41.
Feulner JA, Lu M., Shelton JM, Zhang M., Richardson JA, Munford RSIdentification of acyloxyacyl hydrolase, a lipopolysaccharide-detoxifying enzyme, in the murine urinary tract. Infect Immun2004; 72: 3171—3178.
42.
Peterson AA , Munford RSDephosphorylation of the lipid A moiety of Escherichia coli lipopolysaccharide by mouse macrophages. Infect Immun.1987; 55: 974—978.
43.
Hampton RY, Golenbock DT, Raetz Crh.Lipopolysaccharide stimulation regulates lipid A metabolism in macrophage cell lines. FASEB J1990; 4: A1908.
44.
Bentala H., Verweij WR, Huizinga-Van der Vlag A., Loenen-Weemaes AM, Meijer DK, Poelstra K.Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide . Shock2002; 18: 561—566.
45.
Koyama I., Matsunaga T., Harada T., Hokari S., Komoda T.Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem2002; 35: 455—461.
46.
Beumer C., Wulferink M., Raaben W., Fiechter D., Brands R., Seinen W.Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther2003; 307: 737—744.
47.
Verweij WR, Bentala H., Huizinga-Van der Vlag A. et al. Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock2004; 22: 174—179.
48.
Munford RSDeacylation of bacterial endotoxins by neutrophils and macrophages: early observations and hypotheses. Methods Find Exp Clin Pharmacol1986; 8: 63—65.
49.
Mathison JC , Ulevitch RJThe clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol1979; 123: 2133—2143.
50.
Freudenberg N., Freudenberg MA, Bandara K., Galanos C.Distribution and localization of endotoxin in the reticuloendothelial system (RES) and in the main vessels of the rat during shock. Pathol Res Pract1985; 179: 517—527.
51.
Coulthard MG , Swindle J., Munford RS, Gerard RD, Meidell RSAdenovirus-mediated transfer of a gene encoding acyloxyacyl hydrolase (AOAH) into mice increases tissue and plasma AOAH activity . Infect Immun1996; 64: 1510—1515.
52.
Ge Y., Ezzell RM, Tompkins RG, Warren HSCellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis1994; 169: 95—104.
53.
Rogers DEHost mechanisms which act to remove bacteria from the blood stream . Bacteriol Rev1960; 24: 50—66.
54.
Munford RS, Hall CL, Lipton JM, Dietschy JMBiological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides . J Clin Invest1982; 70: 877—888.
55.
Skarnes RCIn vivo distribution and detoxification of endotoxins. In: Berry LJ. (ed) Handbook of Endotoxin, vol. 3: Cellular Biology of Endotoxin. Amsterdam: Elsevier, 1985; 56—81.
56.
Jacob AI, Goldberg PK, Bloom N., Degenshein GA, Kozinn PJEndotoxin and bacteria in portal blood. Gastroenterology1977; 72: 1268—1270.
57.
Lumsden AB, Henderson JM, Kutner MHEndotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology1988; 8: 232—236.
58.
Knolle PA, Gerken G.Local control of the immune response in the liver. Immunol Rev2000; 174: 21—34.
59.
Knolle PA, Löser E., Protzer U. et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol1997; 107: 555—561.
60.
Freudenberg MA, Galanos C.Alterations in rats in vivo of the chemical structure of lipopolysaccharide from Salmonella abortus equi . Eur J Biochem1985; 152: 353—359.
61.
Fox ES, Thomas P., Broitman SAUptake and modification of 125I-lipopolysaccharide by isolated rat Kupffer cells. Hepatology1988; 8: 1550—1554.
62.
Fukuda I., Tanamoto K., Kanegasaki S., Yajima Y., Goto Y.Deacylation of bacterial lipopolysaccharide in rat hepatocytes in vitro. Br J Exp Pathol1989; 70: 267—274.
63.
Sly LM, Rauh MJ, Kalesnikoff J., Song CH, Krystal G.LPS-Induced upregulation of SHIP is essential for endotoxin tolerance . Immunity2004; 21: 227—239.
64.
Cross ASEndotoxin tolerance — current concepts in historical perspective . J Endotoxin Res2002; 8: 83—98.
65.
van der Poll T., Coyle SM, Barbosa K., Braxton CC, Lowry SFEpinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest1996; 97: 713—719.
66.
Elenkov IJ, Webster E., Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RLHistamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol1998; 161: 2586—2593.
67.
Moore FA, Sauaia A., Moore EE, Haenel JB, Burch JM, Lezotte DCPostinjury multiple organ failure: a bimodal phenomenon. J Trauma1996; 40: 501—510.
68.
Gutsmann T. , Muller M., Carroll SF, MacKenzie RC, Wiese A., Seydel U.Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun2001; 69: 6942—6950.
69.
Thompson PA , Tobias PS, Viriyakosol S., Kirkland TN, Kitchens RLLipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem2003 ; 278: 28367—28371.
70.
Jack RS, Fan X., Bernhelden M. et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature1997; 389: 742—744.
71.
Fierer J., Swancutt MA, Heumann D., Golenbock D.The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice. J Immunol2002; 168: 6396—6403.
72.
Yang KK, Dorner BG, Merkel U. et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol2002; 169: 4475—4480.
73.
Wurfel MM, Monks BG, Ingalls RR et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med1997; 186: 2051—2056.
74.
Lamping N., Dettmer R., Schröder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest1998; 101: 2065—2071.
75.
Le Roy D., Di Padova F., Adachi Y., Glauser MP, Calandra T., Heumann D.Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against Gram-negative bacteria. J Immunol2001; 167: 2759—2765.
76.
Zweigner J. , Gramm HJ, Singer OC, Wegscheider K., Schumann RRHigh concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes . Blood2001; 98: 3800—3808.
77.
Haziot A., Rong G-W., Bazil V., Silver J., Goyert SMRecombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol1994; 152: 5868—5876.
78.
Troelstra A. , Giepmans Bng, Van Kessel Kpm, Lichenstein HS, Verhoef J., Van Strijp Jag.Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol1997; 61: 173—178.
79.
Haziot A., Rong GW, Lin XY, Silver J., Goyert SMRecombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol1995; 154: 6529—6532.
80.
Shuto Y., Kataoka M., Higuchi Y., Matsuura K., Hijiya N., Yamamoto S.Roles of CD14 in LPS-induced liver injury and lethality in mice pretreated with Propionibacterium acnes. Immunol Lett2004; 94: 47—55.
81.
Alexis N., Eldridge M., Reed W., Bromberg P., Peden DBCD14-dependent airway neutrophil response to inhaled LPS: role of atopy. J Allergy Clin Immunol2001; 107): 31—35.
82.
Cauwels A., Frei K., Sansano S. et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol1999; 162: 4762—4772.
83.
Pugin J., Ulevitch RJ, Tobias PSA critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med1993; 178: 2193—2200.
84.
Viriyakosol S. , Tobias PS, Kitchens RL, Kirkland TNMD-2 binds to bacterial lipopolysaccharide . J Biol Chem2001; 276: 38044—38051.
85.
Jia HP, Kline JN, Penisten A. et al. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. Am J Physiol2004 ; 287: L428—L437.
86.
Pugin J., Stern-Voeffray S., Daubeuf B., Matthay MA, Elson G., Dunn-Siegrist I.Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood2004: 104: 4071—4079.
87.
Jack DL, Read RC, Tenner AJ, Frosch M., Turner MW, Klein NJMannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis2001; 184: 1152—1162.
Campisi J., Hansen MK, O'Connor KA et al. Circulating cytokines and endotoxin are not necessary for the activation of the sickness or corticosterone response produced by peripheral E. coli challenge. J Appl Physiol2003; 95: 1873—1882.
90.
Ross G., Roth J., Störr B., Voigt K., Zeisberger E.Afferent nerves are involved in the febrile response to injection of LPS into artificial subcutaneous chambers in guinea pigs. Physiol Behav2000; 71: 305—313.
91.
Miyan JA, Broome CS, Afan AMCoordinated host defense through an integration of the neural, immune and haemopoietic systems. Domest AnimalEndocrinol1998; 15: 297—304.
92.
Simons CT, Kulchitsky VA, Sugimoto N., Homer LD, Székely M., Romanovsky AASignaling the brain in systemic inflammation: which vagal branch is involved in fever genesis?Am J Physiol1998 ; 275: R63—R68.
93.
Netea MG, Kullberg B-J., Van der Meer Jwm.Circulating cytokines as mediators of fever. Clin Infect Dis2000; 31: S178-S184.
94.
Dubin W., Martin TR, Swoveland P. et al. Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment. Am J Physiol1996; 270: L736—L744.
95.
Edens HA, Parkos CANeutrophil transendothelial migration and alteration in vascular permeability: focus on neutrophil-derived azurocidin. Curr Opin Hematol2003; 10: 25—30.
96.
Le Barillec K., Pidard D., Balloy V., Chignard M.Human neutrophil cathepsin G down-regulates LPS-mediated monocyte activation through CD14 proteolysis . J Leukoc Biol2000; 68: 209—215.
97.
Thiel M., Caldwell CC, Sitkovsky MVThe critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect2003; 5: 515—526.
98.
Bowler RP, Nicks M., Tran K. et al. Extracellular superoxide dismutase attenuates lipopolysaccharide-induced neutrophilic inflammation. Am J Respir Cell Mol Biol2004; 31: 432—439.
99.
Roth RI, Levin FC, Levin J.Distribution of bacterial endotoxin in human and rabbit blood and effects of stroma-free hemoglobin. Infect Immun1993 ; 61: 3209—3215.
100.
Spek CA, Verbon A., Aberson H. et al. Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J Clin Immunol2003; 23: 132—140.
101.
Levin J., Tomasulo PA, Oser RSDetection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med1970; 75: 903—911.
102.
Warren HS, Novitsky TJ, Ketchum PA, Roslansky PF, Kania S., Siber GRNeutralization of bacterial lipopolysaccharides by human plasma. J Clin Microbiol1985; 22: 590—595.
103.
Von Eschen KB, Rudbach JAInactivation of endotoxin by serum: a phylogenetic study. J Infect Dis1974; 129: 21—27.
104.
Braun JM, Blackwell CC, Poxton IR et al. Proinflammatory responses to lipo-oligosaccharide of Neisseria meningitidis immunotype strains in relation to virulence and disease. J Infect Dis2002; 185: 1431—1438.
105.
Fong Y., Marano MA, Moldawer LL et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest1990 ; 85: 1896—1904.
106.
Greisman SE , Young EJ, Workman JB, Ollodart RM, Hornick RBMechanisms of endotoxin tolerance. The role of the spleen. J Clin Invest1975; 56: 1597—1607.
107.
Pavlov VA, Wang H., Czura CJ, Friedman SG, Tracey KJThe cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation . Mol Med2003; 9: 125—134.
108.
Munford RS , Pugin J.Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med2001; 163: 316—321.
109.
Green PG, Miao Fjp, Levine JD, Levine J.Negative feedback neuroendocrine control of the inflammatory response in rats . J Neurosci1995; 15: 4678—4686.
110.
Strausbaugh HJ, Green PG, Lo E. et al. Pain stimulation suppresses joint inflammation by inducing shedding of L-selectin from neutrophils . Nat Med1999; 5: 1057—1061.
111.
Xia DY, Samols D.Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia . Proc Natl Acad Sci USA1997 ; 94: 2575—2580.
112.
Tilg H., Dinarello CA, Mier JWIL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today1997; 9: 428—432.
113.
Müller B., Peri G., Doni A. et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol2002; 72: 643—649.
114.
Rivera-Chavez FA, Wheeler H., Lindberg G., Munford RS, O'Keefe GE. Regional and systemic cytokine responses to acute inflammation of the vermiform appendix. Ann Surg2003; 237: 408—416.
115.
Lemaire LC , van der Poll T., Van Lanschot JB et al. Minimally invasive surgery induces endotoxin-tolerance in the absence of detectable endotoxemia. J Clin Immunol1998; 18: 414—420.
116.
Cody MJ, Salkowski CA, Henricson BE, Detore GR, Munford RS, Vogel SNEffect of inflammatory and anti-inflammatory stimuli on acyloxyacyl hydrolase gene expression and enzymatic activity in murine macrophages. J Endotoxin Res1997; 4: 371—379.
117.
Lu M., Zhang M., Kitchens RL, Fosmire S., Takashima A., Munford RSStimulus-dependent deacylation of bacterial lipopolysaccharide by dendritic cells. J Exp Med2003; 197: 1745—1754.
Adrie C., Adib-Conquy M., Laurent I. et al. Successful cardiopulmonary resuscitation after cardiac arrest as a `sepsis-like' syndrome. Circulation2002 ; 106: 562—568.
120.
Brandtzaeg P., Osnes L., Ovstebo R., Joo GB, Westvik A-B., Kieruf P.Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med1996; 184: 51—60.
121.
Ertel W., Kremer J-P., Kenney J. et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood1995; 85: 1341—1347.
122.
Dugernier TL, Laterre PF, Wittebole X. et al. Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications . Am J Respir Crit Care Med2003; 168: 148—157.
123.
Arbour NC, Lorenz E., Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet2000; 25: 187—191.
124.
Lorenz E., Mira JP, Frees KL, Schwartz DARelevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med2002; 162: 1028—1032.
125.
Schmitt C. , Humeny A., Becker CM, Brune K., Pahl A.Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem2002; 48: 1661—1667.
126.
Hubacek JA, Stuber F., Frohlich D. et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med2001; 29: 557—561.
127.
Garred P., Strom JJ, Quist L., Taaning E., Madsen HOAssociation of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis2003; 188: 1394—1403.
128.
Barber AE, Coyle SM, Marano MA et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol1993; 150: 1999—2006.
129.
Pollmächer T., Mullington J., Korth C. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis1996; 174: 1040—1045.
130.
Opal SM, Scannon PJ, Vincent JL et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis1999; 180: 1584—1589.
131.
Hurley JCConcordance of endotoxemia with Gram-negative bacteremia — a meta-analysis using receiver operating characteristic curves. Arch Pathol Lab Med2000; 124: 1157—1164.
132.
Munford RS , Hall CLA comparison of two quantitative assays for bacterial lipopolysaccharides. Prog Clin Biol Res1987; 231: 93—102.
133.
Marshall JC , Goster D., Vincent J-L. et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC Study. J Infect Dis2004; 190: 527—534.
134.
Burrell R.Human responses to bacterial endotoxin. Circ Shock1994; 43: 137—153.
135.
Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JEEndotoxemia in human septic shock. Chest1991 ; 99: 169—175.
136.
Namork E., Brandtzaeg P.Fatal meningococcal septicaemia with `blebbing' meningococcus. Lancet2002; 360: 1741.
137.
Brandtzaeg P., Kierulf P., Gaustad P. et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis1989; 159: 195—204.
138.
Greisman SE , Hornick RB, Woodward TEThe role of endotoxin during typhoid fever and tularemia in man. III. Hyperreactivity to endotoxin during infection. J Clin Invest1964; 43: 1747—1757.
139.
Abernathy RS, Spink WWStudies with Brucella endotoxin in humans: the significance of susceptibility to endotoxin in the pathogenesis of brucellosis . J Clin Invest.1958; 37: 219—231.
140.
Greisman SE , Hornick RB, Carozza Jr FA, Woodward TE. The role of endotoxin during typhoid fever and tularemia in man. I. Acquisition of tolerance to endotoxin. J Clin Invest1963 ; 42: 1064—1075.
141.
Hornick RB , Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJTyphoid fever: pathogenesis and immunologic control. N Engl J Med1970; 283: 739—746.
142.
House D., Chinh NT, Hien TT et al. Cytokine release by lipopolysaccharide-stimulated whole blood from patients with typhoid fever. J Infect Dis2002; 186: 240—245.
143.
Freudenberg MA , Merlin T., Sing A., Galanos C.Bacteria-induced hypersensitivity to endotoxin . In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Marcel Dekker , 1999; 719—733.
144.
Matsuura M. , Galanos C.Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium . Infect Immun1990; 58: 935—937.
145.
Ozmen L., Pericin M., Hakimi J. et al. Interleukin 12, interferon gamma, and tumor necrosis factor α are the key cytokines of the generalized Shwartzman reaction. J Exp Med1994; 180: 907—915.
146.
Latour J-G. , McKay DGRequirement of the adrenal glands for provocation of the generalized Shwartzman reaction. Lab Invest1970; 22: 281—285.
Harrison OB , Robertson BD, Faust SN et al. Analysis of pathogen—host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo. Infect Immun2002; 70: 5193—5201.
149.
Greisman SE , Johnston CAEvidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis. J Endotoxin Res1996; 4: 123—153.
150.
Bhat NM, Bieber MM, Chapman CJ, Stevenson FK, Teng Nnh.Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol1993; 151: 5011—5021.
151.
McCloskey RV, Straube RC, Sanders C., Smith SM, Smith CR, CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med1994; 121: 1—5.
152.
Warren HS, Amato SF, Fitting C. et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med1993; 177: 89—97.
153.
Haque KN, Zaidi MH, Bahakim H.IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis . Am J Dis Child1988; 142: 1293—1296.
154.
Hurley JC, Levin J.Endotoxin detection in sepsis. In: Brade H , Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York : Marcel Dekker, 1999; 841—854.
155.
Bates DW, Parsonnet J., Ketchum PA et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. Clin Infect Dis1998; 27: 582—591.
156.
Hurley JCEndotoxemia and Gram-negative bacteremia as predictors of outcome in sepsis: a meta-analysis using ROC curves. J Endotoxin Res2003; 9: 271—279.
157.
Levin M., Quint PA, Goldstein B. et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet2000; 356: 961—967.
158.
Lynn M., Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis2003; 187: 631—639.
159.
Munford RS , Tracey KJIs severe sepsis a neuroendocrine disease?Mol Med2002; 8: 437—442.
160.
Minneci PC , Deans KJ, Banks SM, Eichacker PQ, Natanson C.Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med2004; 141: 47—56.
161.
Keh D., Boehnke T., Weber-Cartens S. et al. Immunologic and hemodynamic effects of `low-dose' hydrocortisone in septic shock — a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med2003; 167: 512—520.
162.
Yang H., Ochani M., Li J. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA2004; 101: 296—301.
163.
Kurahashi K., Kajikawa O., Sawa T. et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest1999; 104: 743—750.
164.
Matute-Bello G., Frevert CW, Kajikawa O. et al. Septic shock and acute lung injury in rabbits with peritonitis — failure of the neutrophil response to localized infection. Am J Respir Crit Care Med2001; 163: 234—243.
165.
Goldfarb RD , Parker TS, Levine DM et al. Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis . Am J Physiol2002; 284: R550—R557.
166.
Reichl D.Extravascular circulation of lipoproteins: their role in reverse transport of cholesterol. Atherosclerosis1994; 105: 117—129.
